Background
Psoriatic arthritis (PsA) is a member of the spondyloarthropathies (SpA) family of diseases, a diverse group of chronic inflammatory rheumatic disorders with common clinical, radiographic, and genetic features [
1,
2]. There are a wide variety of clinical and anatomic characteristics that distinguish PsA from other chronic rheumatic diseases such as rheumatoid arthritis (RA) and other forms of SpA [
3,
4]. The primary regions affected in patients with PsA are the peripheral joints, entheses (connective tissue between tendon or ligament and bone), and axial sites, often in an asymmetrical pattern, in addition to psoriasis of the skin and nails [
4,
5]. In addition to the larger joints, the small joints of the fingers, including the distal interphalangeal (DIP) joints—which are generally spared by RA—and toes are also typically involved in PsA [
5]. Further, up to 43% of patients with PsA experience sacroiliitis (inflammation of the sacroiliac [SI] joint) in the spinal column [
6]. Dactylitis (swelling of an entire digit) is also common in patients with PsA and is a marker of disease progression [
7]. Although PsA is commonly associated with the presence of psoriasis, skin disease and joint inflammation do not always present concurrently [
2].
The prevalence of PsA in the United States is 0.25% [
8]. However, the prevalence of PsA in patients with psoriasis is substantially higher, with approximately 30% of individuals reported to have both conditions [
9]. PsA is reportedly more common in women than in men compared with ankylosing spondylitis [
5,
10]. Although it is important to recognize that there may be some degree of selection bias in this regard (due to conventional wisdom and teaching that women are unlikely to develop ankylosing spondylitis).
The differentiation of PsA from RA can be aided by certain clinical characteristics. Unlike RA, PsA is not associated with circulating autoantibodies [
3,
11]. Patients with PsA are usually seronegative (absence of circulating rheumatoid factor) and a negative test for rheumatoid factor is one component of the ClASsification criteria for Psoriatic Arthritis (CASPAR) [
2,
12]. Additionally, PsA and RA typically have distinct patterns of inflammatory joint damage, which can be distinguished through specific clinical and radiological changes. The clinical pathology of PsA typically presents in the distal interphalangeal and axial joints, with an asymmetrical distribution, whereas RA is primarily symmetrically distributed in the metacarpophalangeal and wrist joints [
3]. However, PsA may also present as a symmetrical arthropathy or as an oligoarthropathy. The vascular pathology of PsA is distinct from RA and is characterized by a hypervascularized network of elongated, tortuous vessels [
3]. Whereas RA primarily results in bone and cartilage resorption, PsA has both bone destruction and formation traits [
13]. Both patients with RA and PsA experience erosion that leads to resorption of cortical bone, but additional formation of bony spurs is observed along insertion sites of entheses only in patients with PsA [
13].
Like other forms of SpA, susceptibility to PsA is associated with the human leukocyte antigen B27 (HLA-B27) gene [
2]. The strength of the association between HLA-B27 and disease susceptibility varies among different SpA subtypes as well as between ethnic groups and the presence of HLA-B27 in combination with other major histocompatibility complex class alleles may influence the pattern of axial or peripheral disease presentation [
14].
The clinical spectrum of PsA is extremely diverse in both disease severity and tissues affected, and this disorder often occurs in conjunction with several associated comorbidities [
4,
15]. The array of symptoms, coupled with the wide range in severity and disease course, presents difficult challenges for treatment [
16]. Mitigation of risks associated with the disease itself, its treatment, and associated comorbidities are all important considerations when managing patients with PsA (Table
1). This review will discuss and highlight the many risks associated with PsA, with the aim to help improve awareness of risks among physicians and to provide guidance in mitigating these risks.
Table 1
PsA risk framework
Disease-related risks (including functional concerns) |
• Assessment of symptoms (pain, stiffness, swelling, rash) ○ Physical examination ○ Joint examination ○ PASI • Functional assessment ○ Imaging (X-rays, MRI) • Quality of life (social interaction, sexual health, body image) ○ SF-36 subscales ○ EuroQoL-5 dimension ○ PsAQoL ○ Pain Disability Index ○ PsAID ○ Work ability • Documentation of extra-articular manifestations and/or comorbidities • Poor balance/risk of falls ○ Fractures |
Treatment-related risks |
• Contraindications ○ NSAIDs in patients with IBD, CV disease • Adverse events ○ Liver damage with methotrexate (obese patients particularly at risk) • Poor compliance/persistence ○ Reduced efficacy of biologics • Routine laboratory monitoring with biologics • Immunogenicity with biologics |
Psychosocial risks |
• Mental health (particularly depression, but also anxiety) ○ SF-36 subscales ○ PsAID ○ DASS-21 • Alcohol abuse • Self-esteem issues (especially in younger patients) • Social participation ○ PsAID |
Psychosocial risks
The impact of PsA is not limited to the skin and joints and patients often experience substantial impairment in QoL [
71]. There is an increased risk of depression and anxiety in patients with PsA, which can complicate treatment [
71]. Symptoms of depression and anxiety are associated with low treatment adherence in chronic diseases and can impair the ability of patients to self-manage [
72]. Physicians should remain cognizant of depressive behaviors such as alcoholism, nonsocial behavior, drug addiction, and suicide ideation and even though treatment of PsA can improve symptoms of depression and anxiety, it is still important for physicians to identify individuals who would benefit from referral for counseling.
Patients with both PsA and psoriasis experience worse QoL than those with only psoriasis [
73]. Additionally, this difference in QoL was not due to differences in other comorbidities between patients with and without joint involvement [
73]. Collectively, further efforts should be made by physicians to identify patients with PsA who should be referred for counseling as well as to monitor changes in these psychosocial issues over the course of treatment.
Conclusions
Among patients with PsA, a major emphasis of comprehensive care should be aimed at mitigating risks and improving physical health-related QoL. As outlined above, this may be achieved by early diagnosis, prevention of disease progression, treatment of PsA-associated physical morbidity, mitigation of treatment-related risk, and treatment of associated medical comorbidity. Various agents, including newer biologics, have approved indications for use in the PsA population—providing the clinician and patients with choices of agents based on their specific disease symptoms. Overall, management of patients with PsA is complex and requires the adoption of a more patient-focused multidisciplinary approach.
Acknowledgements
Technical assistance with editing and styling of the manuscript for submission was provided by Oxford PharmaGenesis Inc. and was funded by Novartis Pharmaceuticals Corporation.